- Home
- CMS vs NTRA Comparison
CMS vs NTRA Comparison
Compare CMS & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMS
- NTRA
- Stock Information
- Founded
- CMS 1987
- NTRA 2003
- Country
- CMS United States
- NTRA United States
- Employees
- CMS N/A
- NTRA N/A
- Industry
- CMS Power Generation
- NTRA Medical Specialities
- Sector
- CMS Utilities
- NTRA Health Care
- Exchange
- CMS Nasdaq
- NTRA Nasdaq
- Market Cap
- CMS 20.5B
- NTRA 20.6B
- IPO Year
- CMS N/A
- NTRA 2015
- Fundamental
- Price
- CMS $69.50
- NTRA $167.26
- Analyst Decision
- CMS Buy
- NTRA Strong Buy
- Analyst Count
- CMS 15
- NTRA 17
- Target Price
- CMS $69.07
- NTRA $145.00
- AVG Volume (30 Days)
- CMS 2.3M
- NTRA 1.6M
- Earning Date
- CMS 10-31-2024
- NTRA 11-12-2024
- Dividend Yield
- CMS 2.96%
- NTRA N/A
- EPS Growth
- CMS 37.73
- NTRA N/A
- EPS
- CMS 3.50
- NTRA N/A
- Revenue
- CMS $7,476,000,000.00
- NTRA $1,531,955,000.00
- Revenue This Year
- CMS $5.82
- NTRA $42.99
- Revenue Next Year
- CMS $3.41
- NTRA $13.31
- P/E Ratio
- CMS $19.90
- NTRA N/A
- Revenue Growth
- CMS N/A
- NTRA 54.94
- 52 Week Low
- CMS $55.10
- NTRA $53.62
- 52 Week High
- CMS $72.40
- NTRA $171.95
- Technical
- Relative Strength Index (RSI)
- CMS 53.86
- NTRA 71.64
- Support Level
- CMS $68.27
- NTRA $143.20
- Resistance Level
- CMS $69.02
- NTRA $171.95
- Average True Range (ATR)
- CMS 1.15
- NTRA 7.35
- MACD
- CMS 0.17
- NTRA 3.53
- Stochastic Oscillator
- CMS 95.25
- NTRA 90.59
About CMS CMS Energy Corporation
CMS Energy is an energy holding company with three principal businesses. Its regulated utility, Consumers Energy, provides regulated natural gas service to 1.8 million customers and electric service to 1.9 million customers in Michigan. CMS Enterprises is engaged in wholesale power generation, including contracted renewable energy. CMS sold EnerBank in October 2021.
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.